MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER

For a long time, chemotherapy remained the main treatment option for metastatic urothelial carcinoma (mUC). Over the past year, there have been revolutionary changes associated with the approval of five new drugs aimed at blocking the interaction between the surface protein of T-lymphocytes PD-1 and...

Description complète

Détails bibliographiques

Auteurs principaux:	R. A. Gafanov, S. V. Garmash, I. B. Kravtsov, S. V. Fastovets
Format:	Artigo
Langue:	Russo
Publié:	QUASAR, LLC 2018-03-01
Collection:	Исследования и практика в медицине
Sujets:	bladder cancer pd-1 pd-l1 immunotherapy atezolizumab nivolumab pembrolizumab avelumab durvalumab
Accès en ligne:	https://www.rpmj.ru/rpmj/article/view/246
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!